Stacy Plum Appointed as Vice President of Sales at Kyverna Therapeutics
Stacy Plum joins Kyverna Therapeutics as Vice President of Sales, bringing three decades of commercial experience, including more than 15 years in sales.
The Move
- New role
- Vice President of Sales
- Company
- Kyverna Therapeutics
- Previously
- Senior Director, US Commercial Field Account Management, Vertex Pharmaceuticals
- Announced
- October 26, 2026
By the Numbers: Kyverna Therapeutics
- Years in Sales
- 16
- Years at Vertex Pharmaceuticals
- 4
- Employees
- 177
- Funding raised
- $295 million
Data: Crustdata, as of October 27, 2026
Kyverna Therapeutics has appointed Stacy Plum as Vice President of Sales. Plum brings three decades of commercial experience, including more than 15 years in sales, and most recently served as Senior Director, US Commercial Field Account Management at Vertex Pharmaceuticals.
A Track Record In Sales
Plum joins from Vertex Pharmaceuticals, where they held the Senior Director, US Commercial Field Account Management role from December 2021. Before that, Plum advanced at Novartis Oncology from Associate Director of Account Management, Cellular Therapy to Regional Director of Field Account Management, Cell & Gene, beginning in 2017.
Much of the earlier career centered on multiple sclerosis, with roles at Novartis as Senior Area Sales Manager, Multiple Sclerosis Division and Senior MS Account Manager, followed by a position at Genentech. That commercial path started in 1996 at Janssen, where Plum served as District Manager, and also includes a stint as Business Manager at Merck. According to Crustdata people data, the new sales leader holds an MBA in Leadership from Walden University.
Why It Matters For Kyverna Therapeutics
Kyverna Therapeutics is a clinical-stage biopharmaceutical company developing cell therapies for patients with autoimmune disease. Its lead candidate, miv-cel (KYV-101), is an autologous CD19-targeting CAR T-cell therapy. Having completed a registrational trial in stiff person syndrome, the company is now running a second registrational trial in generalized myasthenia gravis.
Crustdata company data shows the Emeryville, California biotech employs 177 people, up 18.8% over 12 months, with 167 based in the United States. Kyverna has raised $295 million in total, including a $100 million post-IPO equity round on December 17, 2025, and counts Gilead Sciences and Bain Capital Life Sciences among its investors.
What's Next
Plum takes charge of sales in October 2026 and joins a growing commercial leadership group that includes a Chief Commercial Officer who started in May 2026 and a Vice President of Commercial Operations who arrived in August 2026. The sales function has welcomed 4 new people over the past 12 months, while the wider business has posted 11 listings in the United States since July 27, including several Medical Science Liaison roles.
Hiro News tracks leadership moves across go-to-market teams every day. People, company and job data in this story comes from Crustdata.
Questions and Answers
Who is the new Vice President of Sales at Kyverna Therapeutics?
Stacy Plum is the new Vice President of Sales at Kyverna Therapeutics, starting in October 2026. Plum joins from Vertex Pharmaceuticals, where they served as Senior Director, US Commercial Field Account Management.
What is Stacy Plum's background?
Plum's commercial career began in 1996 at Janssen. It includes multiple sclerosis roles at Novartis, a position at Genentech, and a rise from Associate Director to Regional Director at Novartis Oncology before the move to Vertex Pharmaceuticals. Plum also held a role at Merck.
What does Kyverna Therapeutics do?
Kyverna Therapeutics is a clinical-stage biopharmaceutical company developing cell therapies for autoimmune disease. Its lead candidate, miv-cel (KYV-101), is an autologous CD19-targeting CAR T-cell therapy. The company is based in Emeryville, California and employs 177 people.
· people and company records, retrieved October 27, 2026. Source: Crustdata.